宫颈癌患者新辅助化疗前后TK1、ID-1水平变化与疗效的关系

doi:10.3969/j.issn.1673-8640.2020.02.003

摘要/Abstract

摘要：

目的探讨宫颈癌患者新辅助化疗前后胸苷激酶1（TK1）、细胞分化抑制因子-1（ID-1）水平变化与化疗疗效的关系。方法选取行新辅助化疗的宫颈癌患者200例,检测化疗前、后的血清TK1、ID-1水平。采用受试者工作特征（ROC）曲线评估各项指标判断宫颈癌化疗有效性的效能。结果 200例宫颈癌患者的化疗有效率为56.00%。化疗无效组化疗后血清TK1、ID-1水平明显高于化疗前（P<0.05）。化疗有效组化疗后血清TK1、ID-1水平明显低于化疗前（P<0.05）。化疗有效组化疗后血清TK1、ID-1水平明显低于化疗无效组（P<0.001）,且化疗后TK1、ID-1水平下降比明显高于化疗无效组（P<0.001）。ROC曲线分析结果显示,TK1下降比判断宫颈癌化疗有效的最佳临界值为>24.0%,曲线下面积（AUC）为0.756,ID-1下降比判断宫颈癌化疗有效的临界值为>36.0%,AUC为0.738,二者联合检测的AUC为0.902。结论 TK1、ID-1可作为评估宫颈癌新辅助化疗疗效的指标,二者联合检测的评价效能更高。

关键词: 胸苷激酶1, 细胞分化抑制因子-1, 新辅助化疗, 疗效, 宫颈癌

Abstract:

Objective To investigate the relationship between the changes of thymidine kinase-1（TK1） and inhibitor-1 of cell differentiation（ID-1） levels and curative effect in cervical cancer patients before and after neoadjuvant chemotherapy. Methods A total of 200 patients with cervical cancer treated with neoadjuvant chemotherapy were enrolled,and serum TK1 and ID-1 levels were determined before and after neoadjuvant chemotherapy. The efficiency of each index for cervical cancer was evaluated by receiver operating characteristic（ROC） curve. Results The effective rate of chemotherapy in 200 patients with cervical cancer was 56.00%. The TK1 and ID-1 levels in patients with ineffective chemotherapy after chemotherapy were higher than those before chemotherapy（P<0.05）. The TK1 and ID-1 levels in patients with effective chemotherapy after chemotherapy were lower than those before chemotherapy（P<0.05）. The TK1 and ID-1 levels in patients with effective chemotherapy after chemotherapy were lower than those in patients with ineffective chemotherapy（P<0.001）,and serum TK1 and ID-1 decline ratios in patients with effective chemotherapy were higher than those in patients with ineffective chemotherapy（P<0.001）. ROC curve analysis showed that the optimal cut-off value of TK1 decline ratio for judging the effectiveness of chemotherapy for cervical cancer was >24.0%,and the area under curve（AUC） was 0.756. The optimal cut-off value of ID-1 decline ratio for judging the effectiveness of chemotherapy for cervical cancer was >36.0%,the AUC was 0.738,and the AUC of TK1 combined with ID-1 was 0.902. Conclusions TK1 and ID-1 can be used as indexes for evaluating the efficiency of chemotherapy,and the determination of TK1 combined with ID-1 is effective.

Key words: Thymidine kinase-1, Inhibitor-1 of cell differentiation, Neoadjuvant chemotherapy, Curative effect, Cervical cancer

中图分类号:

R446.1

张晓英. 宫颈癌患者新辅助化疗前后TK1、ID-1水平变化与疗效的关系[J]. 检验医学, 2020, 35(2): 108-111.

ZHANG Xiaoying. Relationship between the changes of TK1 and ID-1 levels and curative effect in cervical cancer patients before and after neoadjuvant chemotherapy[J]. Laboratory Medicine, 2020, 35(2): 108-111.

图/表 3

参考文献 16

[1]	高立,刘妍. 腹腔镜手术联合新辅助化疗对宫颈癌患者三项血清标志物的影响[J]. 检验医学与临床,2017,14(19):2897-2899.
[2]	闵玲,陈琳娜,钟亮星. 血清E-cad、TK1和SCC在宫颈癌诊断中的价值[J]. 广东医学,2014,35(14):2227-2228.
[3]	马莉娟,何金彩,柴泽英. 细胞分化抑制因子-1与细胞增殖核抗原Ki-67在宫颈癌中的表达及相关性研究[J]. 中国临床药理学杂志,2015,31(8):627-630.
[4]	李媛,段钊. 节拍化疗对局部晚期宫颈癌患者的疗效[J]. 安徽医学,2015,36(4):413-415.
[5]	FARZANEH F,SHAHGHASSEMOUR S,NOSHINE B,et al.Application of tumor markers SCC-Ag,CEA,and TPA in patients with cervical precancerous lesions[J]. Asian Pac J Cancer Prev,2014,15(9): 3911-3914.
[6]	轩乾坤,郭建,吴文娟,等. 人乳头瘤病毒E6/E7 mRNA检测的临床应用[J]. 检验医学,2018,33(7):640-643.
[7]	BUDA A,LISSONI A A,FLORIANI I,et al.Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer:validity of pathological response as surrogate endpoint of survival[J]. Int J Gynecol Cancer,2015,25(8) :1468-1475.
[8]	赵艳芳,王世辉,邹余粮. 顺铂或奈达铂联合紫杉醇治疗宫颈癌的疗效比较[J]. 药物评价研究,2017,40(1):87-91.
[9]	LAPRESA M,PARMA G,PORTUESI R,et al.Neoadjuvant chemotherapy in cervical cancer:an update[J]. Expert Rev Anticancer Ther,2015,15(10):1171-1181.
[10]	SALVATICI M,ACHILARRE M T,SANDRI M T,et al.Squamous cell carcinoma antigen(SCC-Ag) during follow-up of cervical cancer patients:role in the early diagnosis of recurrence[J]. Gynecol Oncol,2016,142(1):115-119.
[11]	史英,柳志宝,赵瑾,等. 肿瘤异常蛋白在乳腺癌患者中的表达及其与化疗效果相关性[J]. 现代仪器与医疗,2016,22(6):97-99.
[12]	WANG Y,JIANG X,DONG S,et al.Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56 286 people[J]. Cancer Biomark,2016,16(4):529-536.
[13]	AGARWAL H K,KHALIL A,ISHITA K,et al.Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer[J]. Eur J Med Chem,2015,100:197-209.
[14]	张鸿艳. 血清E-cad、TK1水平及HPV-DNA分型检测诊断宫颈癌的临床价值[J]. 中国妇幼保健,2017,32(19):4693-4694.
[15]	陈静,李聪. Id-1、VEGF和MMP-9在宫颈鳞状细胞癌中的表达及意义[J]. 临床输血与检验,2016,18(2):137-139.
[16]	ZHAO J,WANG S,LIU N,et al.Correlation between the expression of Id-1 and hyperthermia-associated molecules in oral squamous cell carcinoma[J]. J Clin Pathol,2013,66(9):758-763.

组别	例数	TK1			ID-1
组别	例数	化疗前/（pmol/L）	化疗后/（pmol/L）	下降比/%	化疗前/（μg/L）	化疗后/（μg/L）	下降比/%
化疗有效组	112	12.26±1.62	5.12±0.62^*	50.62±5.63	45.55±4.62	26.36±1.82^*	52.30±5.82
化疗无效组	88	12.20±1.65	14.04±1.72^*	-15.35±2.06	45.79±4.68	51.25±5.01^*	-12.04±2.21
t值		0.200	35.620	45.875	0.281	34.662	48.625
P值		0.842	<0.001	<0.001	0.779	<0.001	<0.001

组别	例数	TK1			ID-1
组别	例数	化疗前/（pmol/L）	化疗后/（pmol/L）	下降比/%	化疗前/（μg/L）	化疗后/（μg/L）	下降比/%
化疗有效组	112	12.26±1.62	5.12±0.62^*	50.62±5.63	45.55±4.62	26.36±1.82^*	52.30±5.82
化疗无效组	88	12.20±1.65	14.04±1.72^*	-15.35±2.06	45.79±4.68	51.25±5.01^*	-12.04±2.21
t值		0.200	35.620	45.875	0.281	34.662	48.625
P值		0.842	<0.001	<0.001	0.779	<0.001	<0.001

项目	例数	AUC	最佳临界值	敏感性 / %	特异性 / %	准确性 / %
TK1下降比	200	0.756	>24.0%	82.14	77.27	80.00
ID-1下降比	200	0.738	>36.0%	85.71	81.82	84.00
联合检测	200	0.902		96.43	95.45	96.00

项目	例数	AUC	最佳临界值	敏感性 / %	特异性 / %	准确性 / %
TK1下降比	200	0.756	>24.0%	82.14	77.27	80.00
ID-1下降比	200	0.738	>36.0%	85.71	81.82	84.00
联合检测	200	0.902		96.43	95.45	96.00